CareDx, Inc.
About CareDx, Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $379.8M
- Net income
- -$21.4M
- Total assets
- $413.2M
- Market cap
- $1.1B
- Operating margin
- -8.1%
- Net margin
- -5.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $379.8M
- Operating expenses
- $410.6M
- Operating income
- -$30.8M
- Income tax
- $271.0K
- Net income
- -$21.4M
- EPS (basic)
- $-0.40
- EPS (diluted)
- $-0.40
Balance sheet
- Total assets
- $413.2M
- Current assets
- $257.1M
- Total liabilities
- $110.1M
- Current liabilities
- $89.8M
- Shareholders’ equity
- $303.1M
Cash flow
- Operating cash flow
- $42.0M
- Investing cash flow
- $2.2M
- Financing cash flow
- -$93.4M
- Net cash flow
- -$49.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.1B
- EPS (diluted)
- $-0.4
- Shares outstanding
- 52.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 17, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $21.4M in FY2025.
- Revenue grew 98% from FY2020 to FY2025.
- Trading 5% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CareDx, Inc..
Write a review
News about CareDx, Inc.
News & sentiment via Polygon.io
